Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Medicine (Baltimore) ; 102(47): e36122, 2023 Nov 24.
Article in English | MEDLINE | ID: mdl-38013289

ABSTRACT

BACKGROUND: We compared the efficacy and safety of low-intensity atorvastatin and ezetimibe combination therapy with moderate-intensity atorvastatin monotherapy in patients requiring cholesterol-lowering therapy. METHODS: At 19 centers in Korea, 290 patients were randomized to 4 groups: atorvastatin 5 mg and ezetimibe 10 mg (A5E), ezetimibe 10 mg (E), atorvastatin 5 mg (A5), and atorvastatin 10 mg (A10). Clinical and laboratory examinations were performed at baseline, and at 4-week and 8-week follow-ups. The primary endpoint was percentage change from baseline in low-density lipoprotein (LDL) cholesterol levels at the 8-week follow-up. Secondary endpoints included percentage changes from baseline in additional lipid parameters. RESULTS: Baseline characteristics were similar among the study groups. At the 8-week follow-up, percentage changes in LDL cholesterol levels were significantly greater in the A5E group (49.2%) than in the E (18.7%), A5 (27.9%), and A10 (36.4%) groups. Similar findings were observed regarding the percentage changes in total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B levels. Triglyceride levels were also significantly decreased in the A5E group than in the E group, whereas high-density lipoprotein levels substantially increased in the A5E group than in the E group. In patients with low- and intermediate-cardiovascular risk, 93.3% achieved the target LDL cholesterol levels in the A5E group, 40.0% in the E group, 66.7% in the A5 group, and 92.9% in the A10 group. In addition, 31.4% of patients in the A5E group, 8.1% in E, 9.7% in A5, and 7.3% in the A10 group reached the target levels of both LDL cholesterol < 70 mg/dL and reduction of LDL ≥ 50% from baseline. CONCLUSIONS: The addition of ezetimibe to low-intensity atorvastatin had a greater effect on lowering LDL cholesterol than moderate-intensity atorvastatin alone, offering an effective treatment option for cholesterol management, especially in patients with low and intermediate risks.


Subject(s)
Anticholesteremic Agents , Azetidines , Heptanoic Acids , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Hypercholesterolemia , Humans , Atorvastatin/therapeutic use , Anticholesteremic Agents/therapeutic use , Cholesterol, LDL , Hypercholesterolemia/drug therapy , Azetidines/therapeutic use , Heptanoic Acids/adverse effects , Pyrroles/therapeutic use , Drug Therapy, Combination , Ezetimibe/therapeutic use , Cholesterol , Treatment Outcome , Double-Blind Method , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
2.
Korean Circ J ; 42(8): 565-7, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22977454

ABSTRACT

An isolated single coronary artery is rare but often associated with other congenital cardiac malformations and myocardial ischemia. We report a rare case of right ventricular myocardial infarction due to total occlusion of the right coronary artery originating from the distal left circumflex artery.

4.
Yonsei Med J ; 51(5): 676-82, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20635441

ABSTRACT

PURPOSE: Metabolic syndrome (MS) has been reported as a potential risk factor of coronary artery disease (CAD). The aims of this study were to assess whether there was a relationship between MS score and CAD angiographic severity, and to assess the predictive value of individual components of MS for CAD. MATERIALS AND METHODS: We retrospectively enrolled 632 patients who underwent coronary angiography for suspected CAD (394 men, 61.0 +/- 10.6 years of age). MS was defined by the National Cholesterol Education Program criteria with the waist criterion modified into a body mass index (BMI) of more than 25 kg/m(2). The MS score defined as the number of MS components. CAD was defined as > 50% luminal diameter stenosis of at least one major epicardial coronary artery. CAD angiographic severity was evaluated with a Gensini scoring system. RESULTS: Of the patients, 497 (78.6%) had CAD and 283 (44.8%) were diagnosed with MS. The MS score was significantly related to the Gensini score. High fasting blood glucose (FBG) was the only predictive factor for CAD. A cluster including high FBG, high blood pressure (BP), and low high-density lipoprotein cholesterol (HDL-C) showed the highest CAD risk. CONCLUSION: The MS score correlates with the angiographic severity of CAD. The predictive ability of MS for CAD was carried almost completely by high FBG, and individual traits with high BP and low HDLC may act synergistically as risk factors for CAD.


Subject(s)
Coronary Angiography , Coronary Artery Disease/complications , Metabolic Syndrome/complications , Aged , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/etiology , Female , Humans , Male , Metabolic Syndrome/diagnostic imaging , Middle Aged , Retrospective Studies , Risk Factors , Severity of Illness Index
5.
Angiology ; 59(6): 676-81, 2008.
Article in English | MEDLINE | ID: mdl-18388053

ABSTRACT

The beneficial effect of beta-blockers is reported in myocardial infarction (MI). This study compared the effects of propranolol and carvedilol on left-ventricular (LV) volume and function after acute MI. Serial echocardiographic studies were performed on acute MI patients who were treated with primary coronary stenting and medical treatment, including propranolol or carvedilol. Determinants of the changes in LV volume and function were identified by regression analyses. At 6 months, there was no significant difference in change in the LV end-diastolic volume between patients receiving 2 beta-blockers. The increase of LV ejection fraction was greater in patients receiving carvedilol. On multivariate analyses, it was found that the kind of beta-blocker had no significant influence on the changes in LV volume or ejection fraction, whereas gender and baseline LV ejection fraction were predictive of change in LV ejection fraction. Compared with propranolol, carvedilol did not have a significant benefit on LV remodeling or function after primary coronary stenting in acute MI.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Angioplasty, Balloon, Coronary/instrumentation , Carbazoles/therapeutic use , Heart Ventricles/drug effects , Myocardial Infarction/therapy , Propanolamines/therapeutic use , Propranolol/therapeutic use , Stents , Ventricular Function, Left/drug effects , Aged , Blood Pressure/drug effects , Carvedilol , Female , Heart Rate/drug effects , Heart Ventricles/diagnostic imaging , Heart Ventricles/physiopathology , Humans , Male , Middle Aged , Myocardial Infarction/drug therapy , Myocardial Infarction/physiopathology , Retrospective Studies , Stroke Volume/drug effects , Time Factors , Treatment Outcome , Ultrasonography
6.
Korean J Intern Med ; 22(4): 296-9, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18309692

ABSTRACT

Primary duodenal mucosa associated lymphoid tissue (MALT) lymphoma is very rare, and little is known about its clinical course or effective treatment. We describe a case of primary duodenal MALT lymphoma that was resistant to Helicobacter pylon (H. pylori) eradication and regressed after chemotherapy with cyclophosphamide, vincristine, and prednisolone (CVP). A 71-year-old woman was referred to our department because of epigastric pain and dyspepsia. Gastroduodenoscopy revealed an irregular mucosal nodular lesion with ulceration extending from the bulb to the second portion of the duodenum. Histopathological examination of a biopsy specimen disclosed low-grade MALT lymphoma composed of atypical lymphoid cells with lymphoepithelial lesion. Abdominal CT scans revealed 0.5 to 1.5 cm lymph nodes in the peritoneal cavity, suggestive of lymph node metastasis. We successfully eradicated H. pylori but did not see signs of remission. We administered systemic CVP chemotherapy every 3 weeks. After 6 courses of CVP, the patient achieved complete remission and was followed up without recurrence for about a year.


Subject(s)
Duodenum/pathology , Lymphoma, B-Cell, Marginal Zone/pathology , Aged , Antineoplastic Protocols , Cyclophosphamide , Female , Helicobacter Infections , Humans , Lymphoma, B-Cell, Marginal Zone/diagnosis , Prednisolone , Vincristine
7.
Clin Cardiol ; 29(9): 418-20, 2006 Sep.
Article in English | MEDLINE | ID: mdl-17007175

ABSTRACT

In some patients with acute myocardial infarction (MI), wall motion in the noninfarcted area declines globally despite localized myocardial damage. In most, an infarct-related lesion is the proximal part of the left anterior descending artery (LAD). Previous studies have reported that hypokinesis of remote myocardium may be related to multivessel disease, impaired coronary flow, or coronary flow reserve in nonculprit arteries. This report describes the case of a 53-year-old man who presented with severe global left ventricular (LV) dysfunction after an acute MI associated with distal LAD occlusion. Follow-up echocardiographic examination revealed nearly normalized LV function 5 days after the episode. We discuss a plausible mechanism of dysfunction of noninfarcted myocardium.


Subject(s)
Coronary Stenosis/complications , Coronary Stenosis/physiopathology , Myocardial Infarction/complications , Myocardial Infarction/physiopathology , Ventricular Dysfunction, Left/etiology , Ventricular Dysfunction, Left/physiopathology , Angioplasty, Balloon, Coronary , Blood Flow Velocity , Coronary Angiography , Coronary Circulation , Coronary Stenosis/diagnosis , Coronary Stenosis/therapy , Echocardiography , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/therapy , Stroke Volume , Ventricular Dysfunction, Left/diagnosis , Ventricular Dysfunction, Left/therapy
8.
Coron Artery Dis ; 17(3): 249-53, 2006 May.
Article in English | MEDLINE | ID: mdl-16728875

ABSTRACT

OBJECTIVES: Although cardiac troponin I is widely used as a marker for myocardial infarction, its minor elevations are also observed in other clinical situations, and the prognostic factors in such clinical settings have not been well established. The aim of this study was to identify predictors of mortality in patients with minor troponin elevations without an acute myocardial infarction. METHODS: We consecutively enrolled 134 patients from the emergency department with a peak troponin I level greater than the lower limit of detectability (0.04 ng/ml) but less than the 10% coefficient of variation cutoff value for diagnosis of myocardial infarction (0.26 ng/ml). These patients had chest pain or nonspecific symptoms of a circulatory abnormality but lacked the traditional features of an acute myocardial infarction. End point was defined as death from all causes. Cox regression analysis was used to test relations between clinical and biochemical variables and the outcome. RESULTS: During the follow-up of 7.6+/-7.4 months, 12 patients died. Age, log creatine kinase myocardial isoform, and log C-reactive protein were found to be significantly correlated with death. After adjusting for possible confounders in the multivariate model, age (hazard ratio 1.09, confidence interval 1.02-1.16, P=0.012), log creatine kinase myocardial isoform (hazard ratio 13.11, confidence interval 2.01-85.52, P=0.007), and log C-reactive protein (hazard ratio 1.64, confidence interval 1.02-2.56, P=0.041) were identified as independent predictors of mortality. CONCLUSIONS: Creatine kinase myocardial isoform and C-reactive protein levels and age can be integrated to risk-stratify patients with minor troponin I elevation for reasons other than acute myocardial infarction.


Subject(s)
Myocardial Infarction/blood , Myocardial Infarction/diagnosis , Troponin I/blood , Adult , Aged , Aged, 80 and over , Analysis of Variance , Biomarkers/blood , C-Reactive Protein/metabolism , Coronary Artery Disease/blood , Creatine Kinase, MB Form/blood , Female , Follow-Up Studies , Humans , Inflammation Mediators/blood , Korea , Male , Middle Aged , Myocardial Infarction/mortality , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Research Design , Risk Factors , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...